[Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method].
Our clinical and statistical evaluation of Sulpiride and  Perphenazine was carried out over a 10 week period, in 82 patients of both sexes, aged 20 to 56 years. All were chronic patients with a symptomatic profile of apathy, lack of initiative but with the personality relatively well preserved in 56 patients. The daily dosage varied from 300 to 1,200 mg Sulpiride orally and 12 to 48 mg Perphenazine. The effects of therapy have been received globally and individually at the beginning, 4th, 8th, and the end of the 10th week using the B.P.R.S. modified by the clinic of Neurology and Psychiatry of the University of Hiroshima. Using "Armitage's Restricted Sequential Design", there was no significant difference between the therapeutic effects of these 2 neuroleptics. However, Sulpiride appeared more beneficial following the review during the 8th week and the 4th week.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010546:Perphenazine / Q000627:therapeutic use*; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*; D013469:Sulpiride / Q000627:therapeutic use*
D010919:Placebos; D013469:Sulpiride; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D010546:Perphenazine; D001663:Bilirubin
Etude des effets cliniques du sulpiride et de la perphénazine chez 82 schizophrènes par la méthode du double aveugle